Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma

Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma

Doxorubicin (doxo) remains the standard of care for patients with advanced soft tissue sarcoma (STS), even though response rates to doxo are only around 14% to 18%. We evaluated enapotamab vedotin (EnaV), an AXL-specific antibody-drug conjugate (ADC), in a panel of STS patient-derived xenografts (PD...

Full description

Bibliographic Details
Main Authors: Castro, P.G (Author), Franken, P. (Author), Pencheva, N. (Author), Renterghem, B.V (Author), Schöffski, P. (Author), Sciot, R. (Author), Wozniak, A. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
antibody-drug conjugate
AXL
enapotamab vedotin
HuMAX-AXL-ADC
patient-derived xenografts
soft tissue sarcoma
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items